Welcome to our dedicated page for Aptorum Group news (Ticker: APM), a resource for investors and traders seeking the latest updates and insights on Aptorum Group stock.
Aptorum Group Limited reports developments as a pharmaceutical company focused on discovering, developing and commercializing therapeutic assets for diseases with unmet medical needs. Its disclosed program areas include oncology, including orphan oncology indications, and infectious diseases, with pipeline references such as SACT-1 for neuroblastoma and ALS-4 for bacterial infections caused by Staphylococcus aureus, including MRSA.
Recurring APM news includes clinical and regulatory disclosures, operating and financial results, material agreements, shareholder voting matters, governance updates, capital-structure disclosures and Nasdaq listing-compliance communications.
Aptorum Group (NASDAQ: APM) announced that the closing of its merger with DiamiR Biosciences is anticipated on or about July 20, 2026, after which the combined company will be named Niki BioSolutions, Inc. and trade on Nasdaq under ticker “NIKI” on a split-adjusted basis.
In connection with the Merger, Aptorum plans a 1-for-10 reverse share split of its class A and class B ordinary shares, reducing outstanding class A shares from about 6,346,823 to 634,682 and class B shares from about 1,796,934 to 179,693. The reverse split, approved on June 9, 2026, is intended to support compliance with Nasdaq’s minimum bid price requirement and will be accompanied by a redomestication to Delaware. According to Aptorum, the split applies uniformly, does not change any shareholder’s percentage ownership (before merger issuances), adjusts options, warrants and convertible securities proportionally, and does not affect the post-merger entity’s shares.
Aptorum Group (NASDAQ: APM) and DiamiR Biosciences announced three scientific presentations at the 2026 Alzheimer’s Association International Conference (AAIC) in London and online, July 11-15, 2026.
Presentations cover plasma-based APOE genotyping, blood microRNA biomarkers for Alzheimer’s progression, and automated APOE genotyping for point-of-care use.
Aptorum Group (NASDAQ: APM) announced a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics to generate blood-based biomarker data focused on Alzheimer’s disease.
The study will measure biomarkers such as p-Tau 217, amyloid 42/40 and neurofilament light in plasma samples with amyloid status confirmed by amyloid PET, and assess panels alone and combined with DiamiR’s CogniMIR microRNA platform.
Aptorum Group (NASDAQ: APM) announced that its shareholders and DiamiR Biosciences shareholders approved their proposed all-stock merger at meetings held June 9, 2026. The deal would make DiamiR a wholly owned subsidiary of Aptorum, subject to remaining customary closing conditions, with closing expected before fiscal 2027.
Aptorum Group (NASDAQ: APM) and DiamiR Biosciences announced publication of a study titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics on March 10, 2026. The peer-reviewed study, conducted with the University of Pennsylvania, shows feasibility of detecting glioblastoma via a minimally invasive blood plasma microRNA test, identifying specific microRNA signatures with potential diagnostic and monitoring utility versus invasive biopsies or costly imaging.
Aptorum Group (NASDAQ: APM) announced receipt of a Nasdaq notification dated March 5, 2026, for non-compliance with the $1 minimum bid price under Nasdaq Listing Rule 5550(a)(2).
The notification does not affect current trading. Aptorum has a 180-calendar-day cure period until September 1, 2026, to regain compliance and is evaluating options, including a possible reverse stock split, to restore compliance.
Aptorum Group (NASDAQ: APM) announced a collaboration between DiamiR Biosciences and Instant NanoBiosensors to validate INB’s automated G8 Genotyping Analyzer for APOE testing in DiamiR’s CLIA-certified, CAP-accredited laboratory.
The project will compare INB’s platform to DiamiR’s New York State approved APOE test to evaluate analytical performance, clinical suitability, and potential to increase testing throughput. Financial terms were not disclosed.
DiamiR Biosciences and Aptorum Group (NASDAQ: APM) announced two poster presentations accepted for the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Dec 1–4, 2025 in San Diego and online. The posters focus on brain-enriched and inflammation-associated microRNAs as plasma epigenetic biomarkers to classify cognitively unimpaired, MCI, and AD participants and to characterize stages of neurodegeneration.
Presentations occur in the Clinical Trials: Biomarkers session on Dec 3, 2025 (7:15 AM–5:30 PM PST) at the Hilton San Diego Bayfront; poster #225 was conducted with NYU ADRC (grant P30AG066512) and poster #240 with UPenn ADRC. Studies were funded by NIA SBIR grant R44AG044860.
Aptorum Group (NASDAQ: APM) priced a registered direct offering of 1,000,000 Class A ordinary shares at $2.00 per share for expected gross proceeds of $2.0 million, with a concurrent private placement of unregistered warrants to buy up to 2,000,000 shares at $2.00 per share. Closing is expected on or about October 14, 2025, subject to customary conditions.
The warrants are exercisable upon issuance, expire 24 months after effectiveness of a resale registration statement, and could provide up to $4.0 million additional gross proceeds if fully exercised. Net proceeds are intended to fund expenses tied to the planned merger with DiamiR Biosciences and general working capital; the merger remains subject to contingencies including shareholder approval.
Aptorum Group (NASDAQ: APM) announced board and management changes tied to its planned all-stock merger with DiamiR Biosciences, expected to close in Q4 2025. Upon closing, DiamiR will become a wholly owned subsidiary and Aptorum will add Dr. Laura A. Philips as an independent director. DiamiR co-founder Dr. Kira Sheinerman will join the combined board as a director, and DiamiR CEO Dr. Alidad Mireskandari will join as President and Chief Operating Officer and take a board observer seat. The announcement highlights added expertise in molecular diagnostics, Alzheimer’s early-detection tests, and commercialization experience for the combined company.